Aprea Therapeutics (NASDAQ:APRE) Coverage Initiated by Analysts at LADENBURG THALM/SH SH

Analysts at LADENBURG THALM/SH SH assumed coverage on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note issued to investors on Wednesday, Briefing.com reports. The firm set a “buy” rating and a $2.00 price target on the stock. LADENBURG THALM/SH SH’s price objective indicates a potential upside of 233.33% from the company’s current price.

Several other analysts have also recently commented on APRE. Wedbush decreased their price objective on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $2.80.

Aprea Therapeutics Stock Up 1.2%

Aprea Therapeutics stock opened at $0.60 on Wednesday. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $1.69. The stock has a 50-day moving average price of $0.73 and a 200 day moving average price of $0.77.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Wednesday, August 12th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.11. Research analysts anticipate that Aprea Therapeutics will post -0.34 EPS for the current year.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently raised its stake in Aprea Therapeutics stock. AIGH Capital Management LLC grew its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) by 174.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,015,541 shares of the company’s stock after purchasing an additional 645,000 shares during the period. AIGH Capital Management LLC owned about 8.47% of Aprea Therapeutics worth $775,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its research focuses on treatments designed to exploit weaknesses in tumor cells, with an emphasis on DNA damage response and cell-cycle regulation.

The company’s lead investigational program is ATRN-119, an oral, selective inhibitor of ataxia telangiectasia and Rad3-related protein, or ATR. ATRN-119 is being evaluated in early-stage clinical studies for patients with advanced solid tumors.